Novo Nordisk Rejoins British Pharmaceutical Industry Association After Suspension

Novo Nordisk has regained its membership in the Association of the British Pharmaceutical Industry (ABPI) following a two-year suspension. The pharmaceutical company had been temporarily removed from the industry body due to concerns regarding its adherence to ABPI’s code of conduct.

The reinstatement marks the end of a period during which Novo Nordisk faced scrutiny over compliance issues with the association’s ethical and professional standards. ABPI, which represents pharmaceutical companies operating in the UK, enforces strict guidelines aimed at ensuring responsible practices within the industry. Details surrounding the specific compliance concerns that led to Novo Nordisk’s suspension have not been disclosed publicly. However, its return to membership indicates that these matters have been addressed to ABPI’s satisfaction.

Date: 18 March, 2025

Newsflash | Powered by GeneOnline AI

Author

Mark Chiang

Related Post

Regional

Denmark: The Country Behind Ozempic Is Preparing for Life After the GLP-1 Windfall

2026-06-10

GTC 2026

NVIDIA GTC 2026: Must-See Biotech and Pharma AI Breakthroughs Beyond Silicon Photonics and Memory

2026-03-10

Perspectives

The GLP-1 Gold Rush: Lilly, Novo and New Rivals Chase a $260 Billion Market

2026-03-04